January 13, 2021
“AcelRx Pharmaceuticals (ACRX)… Turning now to the rest of the Street, 3 Buys and no Holds or Sells have been published in the last three months. Therefore, ACRX has a Strong Buy consensus rating. Based on the $7 average price target,… Continue Reading…
January 11, 2021
“Union Pacific, Annual Return: 11%… …Railroads also got a big boost in 1980, when the industry was deregulated. Union Pacific shares have generated around 12%, annualized, over the past 40 years, roughly even with the Dow’s return… Altria, Annual Return:… Continue Reading…
December 21, 2020
“Lordstown Motors (RIDE)… Overall, RIDE shares get a Hold from the analyst consensus, reflecting Wall Street caution toward a new – and highly speculative – endeavor. The rating is derived from 4 recent reviews, evenly split between 2 Buys and 2… Continue Reading…
December 9, 2020
“ADMA Biologics (ADMA)… Are other analysts in agreement? They are. Only Buy ratings, 5, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. Given the $6.65 average price target, shares could… Continue Reading…
November 13, 2020
“Telephone & Data Systems… This stock also holds a Strong Buy rating from the analyst consensus, based on 3 unanimous Buy reviews set in recent weeks. Shares are priced at $18.73 and the average target of $34.83 suggests a one-year… Continue Reading…
November 2, 2020
“Alliance Data Systems (ADS)… Overall, ADS has a Strong Buy rating from the analyst consensus, based on 5 Buys and 1 Hold. The stock is selling for $53 and its $71.43 average price target implies an upside of ~35% over… Continue Reading…
October 19, 2020
“Athira Pharma (ATHA)… Judging by the consensus breakdown, opinions are anything but mixed. With 4 Buys and no Holds or Sells assigned in the last three months, the word on the Street is that ATHA is a Strong Buy. At… Continue Reading…
October 15, 2020
“Catalyst Biosciences (CBIO)… Other analysts don’t beg to differ. With 3 Buy ratings and no Holds or Sells, the word on the Street is that CBIO is a Strong Buy. At $19.33, the average price target implies 303% upside potential… Continue Reading…
Recent Comments